Mortality among solid organ waitlist candidates during COVID-19 in the United States.
health services and outcomes research
heart transplantation/cardiology
kidney transplantation/nephrology
kidney transplantation: living donor
liver transplantation/hepatology
lung transplantation: living donor
patient survival
waitlist management
Journal
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
ISSN: 1600-6143
Titre abrégé: Am J Transplant
Pays: United States
ID NLM: 100968638
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
revised:
12
02
2021
received:
10
11
2020
accepted:
15
02
2021
pubmed:
24
2
2021
medline:
22
6
2021
entrez:
23
2
2021
Statut:
ppublish
Résumé
We examined the effects of COVID-19 on solid organ waiting list mortality in the United States and compared effects across patient demographics (e.g., race, age, and sex) and donation service areas. Three separate piecewise exponential survival models estimated for each solid organ the overall, demographic-specific, and donation service area-specific differences in the hazard of waitlist mortality before and after the national emergency declaration on March 13, 2020. Kidney waiting list mortality was higher after than before the national emergency (adjusted hazard ratio [aHR], 1.37; 95% CI, 1.23-1.52). The hazard of waitlist mortality was not significantly different before and after COVID-19 for liver (aHR, 0.94), pancreas (aHR, 1.01), lung (aHR, 1.00), and heart (aHR, 0.94). Kidney candidates had notable variability in differences across donation service areas (aHRs, New York City, 2.52; New Jersey, 1.84; and Michigan, 1.56). The only demographic group with increased waiting list mortality were Blacks versus Whites (aHR, 1.41; 95% CI, 1.07-1.86) for kidney candidates. The first 10 weeks after the declaration of a national emergency had a heterogeneous effect on waitlist mortality rate, varying by geography and ethnicity. This heterogeneity will complicate comparisons of transplant program performance during COVID-19.
Identifiants
pubmed: 33621421
doi: 10.1111/ajt.16550
pmc: PMC8014331
pii: S1600-6135(22)08601-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2262-2268Subventions
Organisme : HRSA HHS
ID : HHSH250201500009C
Pays : United States
Organisme : HRSA HHS
ID : HHSH250201500009C
Pays : United States
Informations de copyright
Published 2021. This article is a U.S. Government work and is in the public domain in the USA.
Références
Lancet Infect Dis. 2020 Jul;20(7):774-775
pubmed: 32243815
Lancet Infect Dis. 2020 Jul;20(7):776-777
pubmed: 32224313
Transplant Rev (Orlando). 2013 Apr;27(2):50-6
pubmed: 23481320
Lancet Infect Dis. 2020 Jul;20(7):773
pubmed: 32171390
JAMA. 2020 May 19;323(19):1891-1892
pubmed: 32293639
Am J Transplant. 2018 Jun;18(6):1360-1369
pubmed: 29397038
JAMA Cardiol. 2020 Sep 01;5(9):1048-1052
pubmed: 32936254
Am J Transplant. 2020 Nov;20(11):3008-3018
pubmed: 32780493
Am J Transplant. 2014 Aug;14(8):1723-30
pubmed: 25040084